S&P 500   4,184.13 (+0.94%)
DOW   33,086.50 (+0.86%)
QQQ   325.09 (+1.04%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,184.13 (+0.94%)
DOW   33,086.50 (+0.86%)
QQQ   325.09 (+1.04%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,184.13 (+0.94%)
DOW   33,086.50 (+0.86%)
QQQ   325.09 (+1.04%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,184.13 (+0.94%)
DOW   33,086.50 (+0.86%)
QQQ   325.09 (+1.04%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Insider Trading & Ownership

$10.63
+0.08 (+0.76%)
(As of 08/8/2022 09:45 AM ET)
Add
Compare
Today's Range
$10.54
$10.68
50-Day Range
$9.31
$11.76
52-Week Range
$9.24
$21.44
Volume
5,861 shs
Average Volume
530,875 shs
Market Capitalization
$600.49 million
P/E Ratio
53.15
Dividend Yield
N/A
Price Target
$12.00

Vanda Pharmaceuticals (NASDAQ:VNDA) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.10%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
7
Amount Of
Insider Selling
(Last 12 Months)
$1.84 M

VNDA Insider Buying and Selling by Quarter

Get VNDA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Vanda Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Vanda Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/28/2022Kevin Patrick MoranCFOSell2,239$10.97$24,561.83117,452  
6/13/2022Stephen Ray MitchellDirectorSell2,700$9.48$25,596.006,515  
5/31/2022Richard W DuganDirectorSell6,500$9.85$64,025.0068,387  
3/2/2022Joakim WijkstromCMOSell6,974$11.19$78,039.06  
3/2/2022Timothy WilliamsSVPSell12,060$11.09$133,745.40  
3/1/2022Kevin Patrick MoranCFOSell3,473$11.19$38,862.87  
3/1/2022Mihael Hristos PolymeropoulosCEOSell7,508$11.19$84,014.52  
12/1/2021Mihael Hristos PolymeropoulosCEOSell46,200$16.00$739,200.00  
9/15/2021Aranthan Jones IIInsiderSell16,824$16.49$277,427.76  
9/9/2021Stephen Ray MitchellDirectorSell19,109$16.74$319,884.6615,200  
8/20/2021Joakim WijkstromCMOSell3,650$15.39$56,173.50  
7/28/2021Kevin Patrick MoranCFOSell2,130$19.24$40,981.2099,296  
7/26/2021Aranthan Jones IIInsiderSell7,250$19.69$142,752.50  
6/14/2021Phaedra ChrousosDirectorSell2,075$19.34$40,130.5012,925  
3/15/2021Aranthan Jones IIInsiderSell18,000$17.72$318,960.00111,935  
3/8/2021Mihael Hristos PolymeropoulosCEOSell175,000$18.00$3,150,000.001,221,062  
3/5/2021Timothy WilliamsSVPSell5,600$17.85$99,960.0092,326  
3/2/2021Gunther BirznieksSVPSell20,465$18.28$374,100.20
2/16/2021Thomas WatkinsDirectorSell5,818$18.54$107,865.7255,323  
12/15/2020Mihael Hristos PolymeropoulosCEOSell125,252$13.04$1,633,286.08
8/20/2020Joakim WijkstromCMOSell3,710$11.08$41,106.8056,290  
8/14/2020Timothy WilliamsSVPSell3,684$11.81$43,508.0479,356  
7/27/2020Aranthan Jones IIInsiderSell7,313$10.62$77,664.0682,687  
5/28/2020Richard W DuganDirectorSell10,129$11.04$111,824.1650,770  
1/2/2020Gian Piero ReverberiSVPSell1,155$16.06$18,549.30166,834  
1/2/2020James Patrick KellyCFOSell4,020$15.94$64,078.80205,726  
1/2/2020Mihael Hristos PolymeropoulosCEOSell9,467$16.00$151,472.001,234,579  
8/26/2019Richard W DuganDirectorSell15,000$14.85$222,750.0050,770  
8/14/2019Timothy WilliamsSVPSell2,575$14.69$37,826.7557,425  
5/21/2019Mihael Hristos PolymeropoulosCEOSell72,872$15.34$1,117,856.481,276,343  
5/17/2019Mihael Hristos PolymeropoulosCEOSell77,225$15.56$1,201,621.001,276,343  
3/4/2019Gian Piero ReverberiSVPSell443$19.92$8,824.56168,432  
3/4/2019James Patrick KellyCFOSell8,751$19.88$173,969.88218,497  
3/4/2019Mihael Hristos PolymeropoulosCEOSell38,166$19.41$740,802.061,217,136  
3/1/2019Gian Piero ReverberiSVPSell438$20.17$8,834.46168,432  
3/1/2019James Patrick KellyCFOSell4,976$20.15$100,266.40218,497  
3/1/2019Mihael Hristos PolymeropoulosCEOSell6,500$20.22$131,430.001,217,136  
1/3/2019James Patrick KellyCFOSell6,061$26.37$159,828.57196,221  
1/3/2019Mihael Hristos PolymeropoulosInsiderSell15,236$26.36$401,620.961,178,872  
1/2/2019Gian Piero ReverberiSVPSell1,130$26.59$30,046.70136,569  
3/1/2018Gunther BirznieksSVPSell8,525$18.72$159,588.00148,366  
3/1/2018James Patrick KellyCFOSell8,532$18.72$159,719.04208,066  
3/1/2018Mihael Hristos PolymeropoulosInsiderSell60,966$18.72$1,141,283.521,243,838  
1/2/2018Gunther BirznieksSVPSell8,568$15.26$130,747.68118,366  
1/2/2018James Patrick KellyCFOSell9,155$15.35$140,529.25144,721  
1/2/2018Mihael Hristos PolymeropoulosInsiderSell191,760$15.30$2,933,928.001,031,848  
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.0012,500  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.4460,772  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88839,178  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.8040,665  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52816,781  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.0015,000  
(Data available from 1/1/2013 forward)












Vanda Pharmaceuticals Insider Trading - Frequently Asked Questions

Who is on Vanda Pharmaceuticals's Insider Roster?

The list of insiders at Vanda Pharmaceuticals includes Aranthan Jones II, Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Joakim Wijkstrom, Kevin Patrick Moran, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins, and Timothy Williams. Learn more on insiders at VNDA.

What percentage of Vanda Pharmaceuticals stock is owned by insiders?

6.10% of Vanda Pharmaceuticals stock is owned by insiders. Learn more on VNDA's insider holdings.

Which Vanda Pharmaceuticals insiders have been selling company stock?

The following insiders have sold Vanda Pharmaceuticals stock in the last 24 months: Aranthan Jones II ($739,140.26), Gunther Birznieks ($374,100.20), Joakim Wijkstrom ($175,319.36), Kevin Patrick Moran ($104,405.90), Mihael Hristos Polymeropoulos ($5,606,500.60), Phaedra Chrousos ($40,130.50), Richard W Dugan ($64,025.00), Stephen Ray Mitchell ($345,480.66), Thomas Watkins ($107,865.72), and Timothy Williams ($277,213.44).

How much insider selling is happening at Vanda Pharmaceuticals?

Insiders have sold a total of 496,221 Vanda Pharmaceuticals shares in the last 24 months for a total of $7,834,181.64 sold.

This page (NASDAQ:VNDA) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.